Press Releases from ENPICOM (13 total)
ENPICOM launches unified bioinformatics platform for lab and AI scientists
's-Hertogenbosch, The Netherlands, October 1, 2024 - ENPICOM, an innovative bioinformatics software engineering company, announces the launch of its new unified bioinformatics solution designed to accelerate biologics discovery and development. The ENPICOM Platform seamlessly integrates AI, data management, and machine learning (ML) frameworks to foster collaboration among lab scientists, data scientists, and ML experts to drive innovation in biologics research.
"The question is no longer whether AI will change our lives,…
ENPICOM secures financing from BOP Capital, BOM Brabant Ventures and brings Dr. …
's-Hertogenbosch, Netherlands - March 21, 2024 - ENPICOM, an innovative bioinformatics software solutions provider, has reached a major milestone by securing additional growth capital from its current investors, BOP Impact Ventures and BOM Brabant Ventures, aimed at expanding the development of ENPICOM's AI assets. Furthermore, the company proudly welcomes Dr. Colby Souders, a seasoned expert in antibody discovery, to its group of investors. This infusion of growth capital not only…
ENPICOM secures extended financing from BOP Capital, BOM Brabant Ventures, Nextg …
s-Hertogenbosch, The Netherlands, June 28, 2023 - ENPICOM, an innovative bioinformatics software engineering company, has successfully secured further financial backing from its current investors BOP Capital, BOM Brabant Ventures, Nextgen Ventures, and Arches Capital. This underscores investor confidence in ENPICOM's vision, unique technological capabilities, and exceptional track record in serving customers in the pharmaceutical and biotech industries.
Recognizing the need for innovative data analysis solutions that provide a comprehensive understanding of…
ENPICOM launches versatile display data analysis solution to accelerate antibody …
ENPICOM, an innovative bioinformatics software company, announced the upcoming expansion of the capabilities of the IGX Platform to unlock seamless analysis of antibody panning data. This major development will allow researchers to analyze antibody display data in an intuitive and visual way, easily perform multi-dataset comparisons, and identify a diverse set of enriched candidates with the best characteristics.
"Our customer-centric approach to product development gives us a close-up view of…
ENPICOM secures Series B funding to scale up operations to meet the high demand …
ENPICOM, an innovative bioinformatics software engineering company, today announced closing of a capital investment round led by BOP Capital. With this additional growth capital, the company can support the rapidly expanding customer base for its unique SaaS proposition, the IGX Platform, to boost the candidate selection processes related to therapeutic antibody discovery. ENPICOM saw a rapid market uptake of its Antibody Discovery Module by Pharma, Biotech and CRO’s after launch…
ENPICOM participates in Inno4vac, a European new public-private partnership to i …
‘s-Hertogenbosch, The Netherlands, October 7, 2021 - Vaccination is one of the most impactful public health interventions in history, saving the lives of an estimated 2.5 million people[1] every year and protecting millions more from illness and disability. Classical vaccine research and development timelines remain nevertheless long and costly, as it takes on average more than 10 years and costs more than €800 million[2] to bring a new vaccine to…
ENPICOM introduces a powerful liability prediction solution to de-risk antibody …
‘s-Hertogenbosch, The Netherlands, September 7, 2021 – ENPICOM, an innovative bioinformatics software company, announced today at the Biologics UK conference new IGX Platform capabilities to accurately annotate exposed liabilities, perform structural modeling of antibodies at scale, and determine developability profiles using customizable penalties. This major development allows researchers to improve their candidate selection by making accurate developability predictions for thousands of sequences at the same time, in a secure, intuitive…
Zai Lab selects ENPICOM’s IGX Platform to leverage new NGS-powered antibody di …
‘s-Hertogenbosch, The Netherlands, May 27, 2021 – ENPICOM, an innovative bioinformatics software engineering company, announced today that Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative, research-based, commercial-stage biopharmaceutical company based in China and the U.S., has signed a subscription agreement for ENPICOM’s IGX Platform. The IGX Platform with its Antibody Discovery Module (ADM) is a software platform engineered to assist researchers in diversifying and improving their candidate pools by…
ENPICOM introduces an end-to-end solution for fast and efficient antibody discov …
‘s-Hertogenbosch (The Netherlands), January 28, 2021 – ENPICOM BV, an innovative bioinformatics software engineering company, announces a major release of its ImmunoGenomiX (IGX) Platform featuring the new Antibody Discovery Module (ADM). This solution will allow scientists in biopharmaceutical companies and academia, as well as service providers working in the antibody discovery field, to make the most of their Sanger and NGS data and independently perform complex analyses.
Addressing the specific needs…
ENPICOM and MiLaboratories join forces to power better Repertoire Sequencing dat …
‘s-Hertogenbosch (The Netherlands) and Solana Beach, CA (United States), December 15, 2020 - ENPICOM BV, an innovative bioinformatics software engineering company, and MiLaboratories LLC, a technology leader in profiling the mammalian adaptive immune system, announced a strategic partnership to enable efficient MiXCR integration into ENPICOM’s cloud-based IGX Platform.
Combining the best of both software solutions within a single platform
MiXCR is a universal, state-of-the-art software solution for annotation and quantification of large-scale…
ENPICOM services Neogene Therapeutics with its T cell repertoire sequencing data …
ENPICOM B.V., an innovative bioinformatics software engineering company delivering ground-breaking products and customized solutions to decode the immune system and improve human health, today announced the company has entered into a service agreement with Neogene Therapeutics to grant the company access to ENPICOM’s cloud-based IGX Platform to manage, organize, and analyze T cell sequencing data. ENPICOM has additionally developed a number of customizations making sure that the platform’s functionality fits…
University Health Network, Canada’s largest research hospital, selects ENPICOM …
The Princess Margaret Cancer Centre, one of the top five cancer research centers in the world, uses ENPICOM’s software to gain insights from the immune system and predict treatment responses in cancer patients
‘s-Hertogenbosch (The Netherlands), September 16, 2020 – ENPICOM, an innovative bioinformatics software engineering company specialized in decoding the immune system, announced that the Princess Margaret Cancer Centre of the University Health Network (UHN) has purchased a subscription to…
ENPICOM deepens insights into the immune system enabling faster precision medici …
's-Hertogenbosch, The Netherlands, March 31, 2020 - ENPICOM, an innovative bioinformatics software engineering company, announced a major release of its ImmunoGenomiX (IGX) Platform. The platform is designed to streamline the analysis and management of vast amounts of repertoire sequencing data, accelerating the discovery and development of new biological targets.
Increased demand for new vaccines and precision medicine, as well as shrinking time-to-market expectations, are contributing to a fundamental shift in how…
Go To Page: 1
